TransCode Therapeutics Inc (RNAZ) concluded trading on Thursday at a closing price of $0.56, with 129.52 million shares of worth about $72.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -97.14% during that period and on May 01, 2025 the price saw a gain of about 38.71%. Currently the company’s common shares owned by public are about 23.34M shares, out of which, 20.98M shares are available for trading.
Stock saw a price change of 41.00% in past 5 days and over the past one month there was a price change of 4.27%. Year-to-date (YTD), RNAZ shares are showing a performance of -83.26% which decreased to -97.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $66.33 during that period. The average intraday trading volume for TransCode Therapeutics Inc shares is 7.15 million. The stock is currently trading 42.71% above its 20-day simple moving average (SMA20), while that difference is down -57.89% for SMA50 and it goes to -93.63% lower than SMA200.
TransCode Therapeutics Inc (NASDAQ: RNAZ) currently have 23.34M outstanding shares and institutions hold larger chunk of about 0.78% of that.
The stock has a current market capitalization of $13.16M and its 3Y-monthly beta is at 1.53. It has posted earnings per share of -$56.61 in the same period. It has Quick Ratio of 2.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNAZ, volatility over the week remained 27.35% while standing at 23.19% over the month.
